FDA Approves Trikafta for Cystic Fibrosis in Children Ages 2-5

The U.S. Food and Drug Administration (FDA) has expanded its approval for elexacaftor, tezacaftor, and ivacaftor (Trikafta) to include children aged 2 to 5 years with cystic fibrosis (CF). This FDA Trikafta approval, previously granted for patients 6 years and older, marks a significant step forward in early intervention for CF patients with at least one F508del mutation.

Drug Overview

Elexacaftor, tezacaftor, and ivacaftor (Trikafta) is a CFTR modulator therapy. It is designed to address the underlying cause of cystic fibrosis. Elexacaftor and tezacaftor act as CFTR correctors, improving the processing and trafficking of the defective CFTR protein. Ivacaftor is a CFTR potentiator that enhances channel gating function. Trikafta is now approved for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene.

Clinical Insights

The extension of approval to children aged 2-5 years is based on pharmacokinetic, safety, and efficacy data from pediatric studies. Clinical trials in older children and adults demonstrated significant improvements in lung function (FEV1), sweat chloride levels, and a reduction in pulmonary exacerbations. The rationale for early treatment is to prevent or delay irreversible lung damage associated with cystic fibrosis.

Regulatory Context

The FDA approval process for CFTR modulators typically involves phased clinical trials, starting with adults and progressing to younger children. [Source: U.S. Food and Drug Administration] Pediatric approvals require additional pharmacokinetic and safety data. Priority review and breakthrough therapy designations have been granted to expedite development, given the unmet medical need in CF. Post-marketing commitments often include long-term safety monitoring.

Market Impact

This FDA elexacaftor tezacaftor ivacaftor approval expands the eligible patient population and reinforces Trikafta's position as a leading CFTR modulator therapy in the U.S. The eligible patient population includes approximately 90% of CF patients with at least one F508del mutation in the US, increasing the addressable market. Trikafta competes with other CFTR modulators such as tezacaftor/ivacaftor and ivacaftor.

Future Outlook

Future milestones may include upcoming label expansions and combination trials. Long-term safety monitoring will continue post-approval.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-08.